In a significant leap for medical logistics and emergency response, Atlanta-based biotech innovator Micron Biomedical has been awarded a $4.5 million contract by the National Institute of Allergy and Infectious Diseases (NIAID). This federal funding, channeled through the NIAID’s Radiation and Nuclear Countermeasures Program, marks a pivotal milestone in the development of the world’s first dissolvable, microarray-based patch designed to combat Acute Radiation Syndrome (ARS).
As global security landscapes shift and the demand for decentralized medical care grows, Micron’s platform offers a paradigm-shifting alternative to traditional hypodermic injections. By replacing cold-chain-dependent, nurse-administered shots with a self-administered, thermostable "button" patch, the company is positioning itself at the forefront of biosecurity and public health readiness.
The Core Innovation: A "Button" to Save Lives
At the heart of the partnership is the integration of Micron’s proprietary dissolvable microarray technology with Connext’s TLR5 agonist, xempritolimod. This combination is specifically engineered to treat ARS, a life-threatening condition resulting from high-dose, acute radiation exposure.
Unlike traditional delivery methods, which require specialized training, sterile environments, and rigorous cold-chain storage, the Micron patch is designed for rapid deployment. The technology functions as a small, adhesive patch—often referred to by CEO Steven Damon as a "button"—that is applied to the skin. Upon activation, the microarray penetrates the superficial layers of the epidermis. Because these microscopic needles bypass the deeper nerve endings, the process is virtually painless. Once the medication is released, the needles dissolve into the skin, and the backing is discarded as standard, non-sharps waste, effectively eliminating the risks associated with needle-stick injuries and biohazard disposal.
A Chronological Evolution: From Georgia Tech to Federal Deployment
The journey of this technology began within the halls of the Georgia Institute of Technology, under the pioneering research of Mark Prausnitz. Recognizing the potential to transform drug delivery, Prausnitz, alongside co-founders Devin McAllister and Sebastien Henry, established Micron Biomedical to transition the technology from the bench to the bedside.
- Foundational Research: The initial development focused on the fundamental engineering of dissolving microneedles. By casting drug solutions into micro-molded templates and utilizing vacuum suction to ensure uniformity, the team successfully created a robust, shelf-stable array.
- The Validation Phase: In 2017, a landmark study published in The Lancet provided clinical validation for the platform. When tested against influenza, the microarray patch demonstrated superior seroconversion rates compared to traditional intramuscular injections. While the results were not statistically significant in every metric, the data proved the platform’s efficacy in triggering immune responses.
- Strategic Partnerships: Following the success of initial trials, Micron sought to broaden its scope. A major partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) was established to adapt the technology for CastleVax’s rapid-response vaccine platform, aimed at compressing development timelines for "Disease X" and future pandemic threats.
- The NIAID Milestone: The announcement on July 27, 2026, regarding the $4.5 million NIAID contract, represents the most significant push toward commercialization. This funding provides the capital necessary to advance the ARS-specific countermeasure through the rigorous regulatory requirements of the FDA.
Technical Superiority and Manufacturing Hurdles
The manufacturing process is as critical to the company’s success as the chemical formulation of the patches. Micron has invested heavily in proprietary, domestically produced manufacturing equipment.
The production cycle involves several sophisticated steps:
- Micro-molding: A liquid drug formulation is cast into a mold.
- Vacuum De-bubbling: A vacuum is applied to ensure the solution fills the microscopic needle cavities entirely, removing any air pockets that could compromise dosage.
- Controlled Drying: This step is crucial; the drying process solidifies the drug, rendering it thermostable. This stability is the key to the product’s strategic value, as it removes the need for expensive and fragile cold-chain logistics.
- Final Assembly: A backing layer is applied, and the finished microarray is prepared for sterile packaging.
CEO Steven Damon emphasizes that while the technology is groundbreaking, it is not a "one-size-fits-all" solution. "We’re dose-limited," Damon notes, "but within that limit, we can handle many, many drugs." The company is currently focused on optimizing this capacity to handle potent, low-volume therapeutics, ensuring that the technology is effective for its intended medical use cases.
Official Perspectives: The Vision for Global Accessibility
In an interview with Drug Discovery and Development, Steven Damon articulated the broader vision for the company: "If something happened, we’d be able to quickly get it to that location and to those people, and they’d be able to self-administer it. It would allow a fast response."
This capability is particularly vital for humanitarian efforts. In regions with limited medical infrastructure, such as parts of sub-Saharan Africa or rural Asia, the lack of trained healthcare workers often prevents the timely administration of life-saving vaccines. Micron’s technology removes these barriers. "They don’t need a doctor to administer it," Damon explains. "They can self-administer it, or a mom can administer it to her child… it can be put on a moped and driven into villages that don’t have access."
This dual-use capability—serving as a high-tech biosecurity tool for the U.S. government while simultaneously providing a low-cost, portable health solution for the developing world—is a rare balance in the biotech industry.
Implications for Public Health and National Security
The implications of the NIAID contract extend far beyond the treatment of radiation injury. By validating the microarray patch as a viable tool for national stockpiling, the federal government is signaling a shift toward more resilient, modular, and decentralized defense strategies.
1. Stockpiling and Biosecurity
The thermostability of the Micron patch is its greatest strategic asset. Traditional stockpiles of vaccines and medicines are often compromised by power outages or equipment failures in cold storage facilities. A stockpiled, room-temperature-stable patch that can be deployed in minutes by untrained personnel provides a level of national security readiness that current injection-based systems cannot match.
2. The Future of Vaccine Distribution
The success of the platform in trials, particularly the higher seroconversion rates seen in influenza studies, suggests that the microneedle approach may be more than just convenient; it may be clinically superior. By delivering medication directly into the skin—which is rich in immune cells—the patch may trigger a more robust and efficient immune response.
3. Regulatory and Commercial Timeline
Micron Biomedical is working toward an ambitious 2028 target for its first market-ready products. The company’s strategy involves a two-pronged approach:
- The "Repurposing" Strategy: Applying the platform to existing, FDA-approved drugs to accelerate the approval timeline.
- The "Novel" Pipeline: Simultaneously pursuing full clinical trials for new, proprietary countermeasures, including the ARS treatment.
"The key to improving that timeline was building out manufacturing," says Damon. "We actually had to invent the equipment, and that equipment is being built domestically. Facilities and manufacturing for commercial-scale production are essential."
Conclusion
As Micron Biomedical moves into this new phase of development, the stakes are high. The intersection of advanced material science and urgent medical need has created a solution that could fundamentally alter how society prepares for, and responds to, disaster. Whether the threat is a radiological event, a global pandemic, or a localized outbreak of preventable disease, the ability to rapidly and easily administer medicine is the ultimate equalizer.
With the backing of the NIAID and a proven track record of innovation, Micron Biomedical is not merely delivering a product; it is building the infrastructure for a more responsive and accessible global health future. The coming years will be critical as the company transitions from the lab to the warehouse, proving that the most effective medical advances are sometimes the ones that fit on the back of a wrist.
About the Author
